EP3011959A1 — Quaternary ammonium compound for use as an inhibitor of protein kinase C alpha
Assigned to Santen SAS · Expires 2016-04-27 · 10y expired
What this patent protects
This invention relates to quaternary ammonium compound for use as an inhibitor of protein kinase C alpha, of formula I: wherein: R 1 is selected from the group of alkyl, alkene, aryl or alkylaryl group; preferably R 1 is a benzyl, alkylbenzyl or alkylphenyl group; more p…
USPTO Abstract
This invention relates to quaternary ammonium compound for use as an inhibitor of protein kinase C alpha, of formula I: wherein: R 1 is selected from the group of alkyl, alkene, aryl or alkylaryl group; preferably R 1 is a benzyl, alkylbenzyl or alkylphenyl group; more preferably benzyl or methylphenyl group; optionally substituted by hydroxyl, oxo, nitro, amido, carboxy, amino, cyano, alkoxy, alkyl, alkene, alkyne, ester or heteroalkyl group. R 2 is an alkyl chain comprising at least 12 carbon atoms; preferably comprising 14, 16 or 18 carbon atoms; R 3 or R 4 are identical or different and each is selected from an alkyl chain; preferably a C1-C4 alkyl chain; more preferably is methyl group. X - is selected from an anion of a pharmaceutically acceptable acid or from halo group; preferably X - is selected from halo group; more preferably is Cl - or Br - . In particular, the present invention relates to a long-chain quaternary ammonium of formula (I) as a wound healing and/or an anti-inflammatory agent for use in the treatment of eye conditions.
Drugs covered by this patent
- Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.